In order to effectively handle collection and analysis of huge volumes of vital data, a leader from IQVIA advises bringing on people up to the challenge.
A leader from the cancer patient matching and analysis solutions firm discusses how and other forces are pushing innovation in the oncology research space.
This year the conference brings its content, focused on the intersection of clinical research and patient care, from the real world to the virtual one.
With the purchase, Syneos Health seeks to strengthen connections with the rapidly growing pre-revenue biopharmaceutical market, and expand global reach.
The two companies are working together to develop AT-527, an orally administered, direct-acting antiviral therapy for patients diagnosed with COVID-19.
A leader from the drug research and development company discusses unique problems faced by COVID-19 patients with prior cancer and autoimmune diagnoses.
The agency has approved the antiviral drug Veklury (remdesivir), produced by Gilead, for hospitalized patients 12 years and over diagnosed with the virus.
The pharmaceutical firm’s More to uS is a UK-centered campaign that shares stories of people living (and thriving) after a multiple sclerosis diagnosis.
The company's Spectus and Percepta platforms offer features to help researchers meet challenges associated with working and collaborating in the pandemic.
eClinical Solutions, a provider of clinical data service solutions, has seen an increase in interest in clinical data platform and other digital products.
A veteran with more than 20 years of experience talks about the vitality of recruiting an inclusive patient population, and the perils of falling short.
As the pandemic maintains its hold, the US agency continues to issue advice and take action related to testing, treatment and information on the virus.
Companies like Biofourmis, THREAD and other virtual tech specialists have seen infusions of funds from investors bullish on decentralized clinical trials.
The survey, unveiled ahead of next week's CPhI Festival of Pharma, reveals perspectives, concerns and future plans of more than 500 industry executives.